Zydus Lifesciences · NSE: ZYDUSLIFE · BSE: 532321

Q1 FY22 results · Apr–Jun 2021

Zydus Lifesciences reported revenue from operations of ₹4,025.40 crore (up 10.6% from Q1 FY21) and net profit of ₹642.50 crore (up 32.0% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY22	Q1 FY21	YoY	Q4 FY21	QoQ
Revenue from operations	4,025.40	3,639.90	+10.6%	3,846.70	+4.6%
Other income	31.60	22.50	+40.4%	(40.30)	Turned profit
Total income	4,057.00	3,662.40	+10.8%	3,806.40	+6.6%
Profit before share of associates & JVs and tax	754.60	593.40	+27.2%	530.00	+42.4%
Share of profit/(loss) of associates & JVs	7.00	16.70		3.80
Net profit for the period	642.50	486.60	+32.0%	735.40	−12.6%
Attributable to shareholders of the company	587.20	454.00	+29.3%	679.00	−13.5%
EPS, basic (₹)	5.74	4.43	+29.6%	6.63	−13.4%
Net margin (%)	16.0	13.4		19.1

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY22	Q1 FY21	YoY	Q4 FY21	QoQ
Revenue from operations	2,123.40	1,795.90	+18.2%	2,018.80	+5.2%
Other income	29.70	20.00	+48.5%	(26.90)	Turned profit
Total income	2,153.10	1,815.90	+18.6%	1,991.90	+8.1%
Profit before tax	486.40	478.40	+1.7%	441.80	+10.1%
Net profit for the period	399.90	398.20	+0.4%	464.70	−13.9%
EPS, basic (₹)	3.91	3.89	+0.5%	4.54	−13.9%
Net margin (%)	18.8	22.2		23.0

Consolidated

Filed with BSE: 11 Aug 2021, 15:11 IST
Board meeting: 11 Aug 2021
Period: 01 Apr 2021 to 30 Jun 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 11 Aug 2021, 15:11 IST
Board meeting: 11 Aug 2021
Period: 01 Apr 2021 to 30 Jun 2021
Review status: Unaudited
Source: XBRL filing on BSE